Shanghai Hile Bio-Technology (SHA:603718) subsidiary Shaanxi Ruisheng Biotechnology will acquire a 51% stake in seven dental clinics in Yangzhou and Changzhou, China, for 61.2 million yuan.
The transaction is expected to contribute 7 million yuan in net profit in 2026, according to a Thusrday filing with the Shanghai bourse.
The clinics will pledge the remaining 49% to Ruisheng Biotechnology to guarantee their performance and impairment compensation obligations, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.